This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Allergan to Buy Keller Funnel, Boost Plastic Surgery Unit
by Zacks Equity Research
Allergan plc (AGN) announced a deal to acquire privately held medical device company Keller Medical, Inc, which makes Keller Funnel, for an undisclosed amount.
Merck's Cancer Drug Keytruda Positive in Clinical Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Amgen Files for Repatha in the U.S., EU for Expanded Use
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.
Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs
by Zacks Equity Research
Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosumab) for an expanded indication at the American Society of Clinical Oncology.
Amgen (AMGN) Down 4.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
Radius Health Osteoporosis Drug Positive in Phase III Study
by Zacks Equity Research
Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months.
Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that Keytruda, has received accelerated approval for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors .
Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
by Zacks Equity Research
Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Amgen Evenity Approval Derailed on Cardiovascular Side Effect
by Zacks Equity Research
A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab
by Zacks Equity Research
Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.
AbbVie Down on Humira Patent Loss: Is More Damage in Store?
by Zacks Equity Research
AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),
Celgene's (CELG) Revlimid Looks Solid on Label Expansion
by Zacks Equity Research
Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.
Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint
by Zacks Equity Research
Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies
Stock Market Today & Weak Retail Earnings
by Sheraz Mian
Today's Research Daily features new research reports on 17 major stocks, including Amazon (AMZN), Verizon (VZ), Citigroup (C) and Amgen (AMGN).
Mylan (MYL) Beats on Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Mylan's (MYL) first-quarter results beat on earnings but missed the top line due to a decline in EpiPen sales.
Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported first-quarter 2017 earnings of 31 cents per share (including the impact of stock-based compensation expenses), down 32.5% from the year-ago figure.
Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View
by Zacks Equity Research
Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.
Celgene vs. Amgen: Which Stock is a Better Pick Post Q1 Earnings?
by Arpita Dutt
Here is a look at how Celgene (CELG) and Amgen (AMGN) fared in the first quarter and which one looks better-positioned for the remainder of the year.
Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a wider-than-expected loss of $1.32 per share in the first quarter of 2017 which were overshadowed by the approval of Tymlos.
Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact
by Zacks Equity Research
Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.
Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up
by Zacks Equity Research
Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.
Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .